News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Two DOACs show similar bleeding risks in head-to-head VTE trial
23 Dec 2025
byAudrey Abella
In a post hoc analysis of the RENOVE trial, the direct oral anticoagulants (DOACs) rivaroxaban and apixaban demonstrate comparable risks of clinically relevant bleeding (CRB) and recurrent venous thromboembolism (VTE). These were observed across the crude, adjusted, and IPTW* analyses.
23 Dec 2025







